COMy 2022 | Approaching R/R multiple myeloma: novel agents and immunotherapies
In this video, Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses treatment approaches for relapsed/refractory (R/R) myeloma, drawing focus on the use of pomalidomide in combination with other agents, such as isatuximab and elotuzumab. Dr Cerchione also discusses the impressive data obtained with other combination approaches, and further highlights the promise of novel agents including belantamab mafodotin and CAR-T cell therapy. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Transcript (edited for clarity)
In relapsed disease, we have new backbones such as pomalidomide starting from second-line of treatments, in combination with isatuximab, elotuzumab and many other agents. I think also the data of isatuximab, carfilzomib, dexamethasone are absolutely impressive in terms of efficacy, progression-free survival and the projection of overall survival.
I think we have a novelty which could really impact on the outcome of our patients...
In relapsed disease, we have new backbones such as pomalidomide starting from second-line of treatments, in combination with isatuximab, elotuzumab and many other agents. I think also the data of isatuximab, carfilzomib, dexamethasone are absolutely impressive in terms of efficacy, progression-free survival and the projection of overall survival.
I think we have a novelty which could really impact on the outcome of our patients. Moreover, the relapsed/refractory setting is being impacted by novel mechanisms of action, such as the anti-BCMA, we have a new target. I think that belantamab mafodotin is confirming this efficacy in terms of therapy as a single agent. But we will see the best is to come when we will touch with our [inaudible 00:00:56] not only clinical trials, but also in our clinical practice. The combinations of belantamab based in relapsed/refractory setting, but in the future thanks to DREAMM-9 data, also in frontline setting.
Moreover, the next future is also from data of bispecific antibodies and the CAR-T treatments, which are achieving impressive data. Not only in later lines, but also in previous line of treatment. I think that this is another great achievement of research in multiple myeloma.
Read more...
